Koselugo approved in the EU for children with neurofibromatosis type 1 and plexiform neurofibromas – AstraZeneca + Merck Inc.
AstraZeneca and MSD’s Koselugo (selumetinib) has been granted conditional approval in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with… read more.
